This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and current algorithms were revised for the 2016 update. The new LCOHs algorithms include clear cell carcinomas, mucinous carcinomas, and grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas. The LCOHs also include carcinosarcomas (malignant mixed Müllerian tumors of the ovary), borderline epithelial tumors (also known as low malignant potential tumors), malignant sex cord-stromal tumors, and malignant germ cell tumors.

  • 1.

    KurmanRJCarcangiuMLHarringtonCS. WHO Classification of Tumours of Female Reproductive Organs4th ed.WHO/IARC Classification of Tumours. Vol. 6. Lyon: IARC Publications; 2014.

    • Search Google Scholar
    • Export Citation
  • 2.

    ChanJKCheungMKHusainA. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol2006;108:521528.

  • 3.

    PratJ. New insights into ovarian cancer pathology. Ann Oncol2012;23(Suppl 10):x111117.

  • 4.

    JelovacDArmstrongDK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin2011;61:183203.

  • 5.

    MorganRJJrCopelandLGershensonD. NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park)1996;10:293310.

    • Search Google Scholar
    • Export Citation
  • 6.

    SiegelRLMillerKDJemalA. Cancer statistics, 2016. CA Cancer J Clin2016;66:730.

  • 7.

    van LeeuwenFEKlipHMooijTM. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod2011;26:34563465.

    • Search Google Scholar
    • Export Citation
  • 8.

    PearceCLTemplemanCRossingMA. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol2012;13:385394.

    • Search Google Scholar
    • Export Citation
  • 9.

    NakonechnyQBGilksCB. Ovarian cancer in hereditary cancer susceptibility syndromes. Surg Pathol Clin2016;9:189199.

  • 10.

    ChuiMHRyanPRadiganJ. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. Am J Surg Pathol2014;38:11731181.

    • Search Google Scholar
    • Export Citation
  • 11.

    LuKHDanielsM. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer2013;12:273277.

    • Search Google Scholar
    • Export Citation
  • 12.

    LancasterJMPowellCBChenLM. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol2015;136:37.

    • Search Google Scholar
    • Export Citation
  • 13.

    RebbeckTRMitraNWanF. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA2015;313:13471361.

    • Search Google Scholar
    • Export Citation
  • 14.

    DalyMBAxilbundJEBuysS. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw2010;8:562594.

  • 15.

    WalshCSBlumAWaltsA. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Gynecol Oncol2010;116:516521.

    • Search Google Scholar
    • Export Citation
  • 16.

    LancasterJMPowellCBKauffND. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol2007;107:159162.

    • Search Google Scholar
    • Export Citation
  • 17.

    ShulmanLP. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Obstet Gynecol Clin North Am2010;37:109133.

    • Search Google Scholar
    • Export Citation
  • 18.

    Bulletins ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome. Gynecol Oncol2009;113:611.

  • 19.

    American College of Obstetricians and GynecologistsACOG Committee on Practice Bulletins–GynecologyACOG Committee on Genetics. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol2009;113:957966.

    • Search Google Scholar
    • Export Citation
  • 20.

    ZhangSRoyerRLiS. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol2011;121:353357.

    • Search Google Scholar
    • Export Citation
  • 21.

    LiuGYangDSunY. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics2012;13:15231535.

  • 22.

    MarchettiCDe FeliceFPalaiaI. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health2014;14:150.

    • Search Google Scholar
    • Export Citation
  • 23.

    ReitsmaWde BockGHOosterwijkJC. Support of the ‘fallopian tube hypothesis’ in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer2013;49:132141.

    • Search Google Scholar
    • Export Citation
  • 24.

    DomchekSMFriebelTMSingerCF. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA2010;304:967975.

    • Search Google Scholar
    • Export Citation
  • 25.

    FinchABeinerMLubinskiJ. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA2006;296:185192.

    • Search Google Scholar
    • Export Citation
  • 26.

    RebbeckTRKauffNDDomchekSM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst2009;101:8087.

    • Search Google Scholar
    • Export Citation
  • 27.

    PowellCBChenLMMcLennanJ. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer2011;21:846851.

    • Search Google Scholar
    • Export Citation
  • 28.

    MingelsMJvan HamMAde KievitIM. Mullerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol. Mod Pathol2014;27:10021013.

    • Search Google Scholar
    • Export Citation
  • 29.

    CallahanMJCrumCPMedeirosF. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol2007;25:39853990.

    • Search Google Scholar
    • Export Citation
  • 30.

    ShermanMEPiedmonteMMaiPL. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol2014;32:32753283.

    • Search Google Scholar
    • Export Citation
  • 31.

    DomchekSMFriebelTMGarberJE. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat2010;124:195203.

    • Search Google Scholar
    • Export Citation
  • 32.

    Clarke-PearsonDL. Clinical practice. Screening for ovarian cancer. N Engl J Med2009;361:170177.

  • 33.

    GoffBAMandelLSDrescherCW. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer2007;109:221227.

    • Search Google Scholar
    • Export Citation
  • 34.

    AndersenMRGoffBALoweKA. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer2008;113:484489.

  • 35.

    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol2011;117:742746.

    • Search Google Scholar
    • Export Citation
  • 36.

    LimAWMesherDGentry-MaharajA. Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes. J Natl Cancer Inst2012;104:114124.

    • Search Google Scholar
    • Export Citation
  • 37.

    RossingMAWicklundKGCushing-HaugenKLWeissNS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst2010;102:222229.

    • Search Google Scholar
    • Export Citation
  • 38.

    GilbertLBassoOSampalisJ. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol2012;13:285291.

    • Search Google Scholar
    • Export Citation
  • 39.

    SmithRAManassaram-BaptisteDBrooksD. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin2015;65:3054.

    • Search Google Scholar
    • Export Citation
  • 40.

    NolenBMLokshinAE. Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol2012;8:5571.

  • 41.

    BuysSSPartridgeEBlackA. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA2011;305:22952303.

    • Search Google Scholar
    • Export Citation
  • 42.

    HartgeP. Designing early detection programs for ovarian cancer. J Natl Cancer Inst2010;102:34.

  • 43.

    MoyerVAU.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med2012;157:900904.

    • Search Google Scholar
    • Export Citation
  • 44.

    Gentry-MaharajAMenonU. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol2012;26:243256.

  • 45.

    SchorgeJOModesittSCColemanRL. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol2010;119:717.

  • 46.

    BrownDLAndreottiRFLeeSI. ACR appropriateness criteria(c) ovarian cancer screening. Ultrasound Q2010;26:219223.

  • 47.

    EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual7th ed.New York: Springer; 2010.

  • 48.

    GilksBMovahedi-LankaraniSBakerPM. Protocol for the examination of specimens from patients with carcinoma of the ovary or fallopian tube. Available at: http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-ovary-fallopian-16protocol-1000.pdf. Accessed August 22 2016.

    • Search Google Scholar
    • Export Citation
  • 49.

    ZeppernickFMeinhold-HeerleinI. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet2014;290:839842.

    • Search Google Scholar
    • Export Citation
  • 50.

    PratJFIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet2014;124:15.

    • Search Google Scholar
    • Export Citation
  • 51.

    McCluggageWG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology2011;43:420432.

    • Search Google Scholar
    • Export Citation
  • 52.

    MalpicaADeaversMTTornosC. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol2007;31:11681174.

    • Search Google Scholar
    • Export Citation
  • 53.

    MalpicaADeaversMTLuK. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol2004;28:496504.

  • 54.

    Movahedi-LankaraniSBakerPMGilksBSoslowRA. Protocol for the examination of specimens from patients with carcinoma of the ovary. Available at: http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/ovary-15protocol-3201.pdf. Accessed August 22 2016.

    • Search Google Scholar
    • Export Citation
  • 55.

    MitchellDGJavittMCGlancP. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol2013;10:822827.

  • 56.

    ImSSGordonANButtinBM. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol2005;105:3541.

  • 57.

    American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol2007;110:201214.

    • Search Google Scholar
    • Export Citation
  • 58.

    DearkingACAlettiGDMcGreeME. How relevant are ACOG and SGO guidelines for referral of adnexal mass?Obstet Gynecol2007;110:841848.

  • 59.

    TimmermanDTestaACBourneT. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol2008;31:681690.

    • Search Google Scholar
    • Export Citation
  • 60.

    IyerVRLeeSI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol2010;194:311321.

    • Search Google Scholar
    • Export Citation
  • 61.

    HarrisRDJavittMCGlancP. ACR Appropriateness Criteria(R) clinically suspected adnexal mass. Ultrasound Q2013;29:7986.

  • 62.

    DodgeJECovensALLacchettiC. Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol2012;19:e244257.

  • 63.

    GregoryJJJrFinlayJL. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Drugs1999;57:463467.

    • Search Google Scholar
    • Export Citation
  • 64.

    SchneiderDTCalaminusGReinhardH. Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96. J Clin Oncol2000;18:832839.

    • Search Google Scholar
    • Export Citation
  • 65.

    KawaiMFuruhashiYKanoT. Alpha-fetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol1990;39:160166.

  • 66.

    YamamotoYOguriHYamadaR. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet2008;102:124127.

    • Search Google Scholar
    • Export Citation
  • 67.

    CastellucciPPerroneAMPicchioM. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun2007;28:589595.

    • Search Google Scholar
    • Export Citation
  • 68.

    RisumSHogdallCLoftA. The diagnostic value of PET/CT for primary ovarian cancer—a prospective study. Gynecol Oncol2007;105:145149.

  • 69.

    CannistraSAGershensonDMRechtA. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVitaVTJrLawrenceTSRosenbergSA eds. DeVita Hellman and Rosenberg's Cancer: Principles & Practice of Oncology10th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2014:10751099.

    • Search Google Scholar
    • Export Citation
  • 70.

    VergoteIDe BrabanterJFylesA. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet2001;357:176182.

    • Search Google Scholar
    • Export Citation
  • 71.

    YoungRH. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol2007;14:149177.

    • Search Google Scholar
    • Export Citation
  • 72.

    LeeKRYoungRH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol2003;27:281292.

    • Search Google Scholar
    • Export Citation
  • 73.

    KimKAParkCMLeeJH. Benign ovarian tumors with solid and cystic components that mimic malignancy. AJR Am J Roentgenol2004;182:12591265.

    • Search Google Scholar
    • Export Citation
  • 74.

    RomagnoloCLeonAEFabricioAS. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecol Oncol2016;141:303311.

    • Search Google Scholar
    • Export Citation
  • 75.

    MooreRGMillerMCDisilvestroP. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol2011;118:280288.

    • Search Google Scholar
    • Export Citation
  • 76.

    YoshidaADerchainSFPittaDR. Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?Gynecol Oncol2016;140:481485.

    • Search Google Scholar
    • Export Citation
  • 77.

    JacobFMeierMCaduffR. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol2011;121:487491.

    • Search Google Scholar
    • Export Citation
  • 78.

    MolinaREscuderoJMAugeJM. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol2011;32:10871095.

    • Search Google Scholar
    • Export Citation
  • 79.

    Van GorpTCadronIDespierreE. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer2011;104:863870.

    • Search Google Scholar
    • Export Citation
  • 80.

    LedermannJALuveroDShaferA. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer2014;24:S1419.

    • Search Google Scholar
    • Export Citation
  • 81.

    KobelMKallogerSEHuntsmanDG. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol2010;29:203211.

    • Search Google Scholar
    • Export Citation
  • 82.

    SeidmanJDHorkayne-SzakalyIHaibaM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol2004;23:4144.

    • Search Google Scholar
    • Export Citation
  • 83.

    RechsteinerMZimmermannAKWildPJ. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol2013;95:235241.

    • Search Google Scholar
    • Export Citation
  • 84.

    VereczkeyISeresterODobosJ. Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res2011;17:551559.

  • 85.

    ReadeCJMcVeyRMToneAA. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can2014;36:133140.

    • Search Google Scholar
    • Export Citation
  • 86.

    VangRShih IeMKurmanRJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol2009;16:267282.

    • Search Google Scholar
    • Export Citation
  • 87.

    Meinhold-HeerleinIBauerschlagDHilpertF. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene2005;24:10531065.

    • Search Google Scholar
    • Export Citation
  • 88.

    GourleyCFarleyJProvencherDM. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer2014;24:S913.

    • Search Google Scholar
    • Export Citation
  • 89.

    Meinhold-HeerleinIFotopoulouCHarterP. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet2016;293:695700.

    • Search Google Scholar
    • Export Citation
  • 90.

    EricksonBKMartinJYShahMM. Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center. Gynecol Oncol2014;133:142146.

    • Search Google Scholar
    • Export Citation
  • 91.

    BristowREChangJZiogasA. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J Am Coll Surg2015;220:940950.

    • Search Google Scholar
    • Export Citation
  • 92.

    LedermannJARajaFAFotopoulouC. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2013;24(Suppl 6):vi2432.

    • Search Google Scholar
    • Export Citation
  • 93.

    BristowREChangJZiogasAAnton-CulverH. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol2013;121:12261234.

    • Search Google Scholar
    • Export Citation
  • 94.

    LearyACowanRChiD. Primary surgery or neoadjuvant chemotherapy in advanced ovarian cancer: the debate continues. Am Soc Clin Oncol Educ Book2016;35:153162.

    • Search Google Scholar
    • Export Citation
  • 95.

    ChiDSBristowREArmstrongDKKarlanBY. Is the easier way ever the better way?J Clin Oncol2011;29:40734075.

  • 96.

    VergoteITropeCGAmantF. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol2011;29:40764078.

    • Search Google Scholar
    • Export Citation
  • 97.

    SchorgeJOGarrettLAGoodmanA. Cytoreductive surgery for advanced ovarian cancer: quo vadis?Oncology (Williston Park)2011;25:928934.

  • 98.

    RosePGNerenstoneSBradyMF. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med2004;351:24892497.

  • 99.

    van der BurgMEvan LentMBuyseM. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med1995;332:629634.

    • Search Google Scholar
    • Export Citation
  • 100.

    ColomboPEMourregotAFabbroM. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol2009;35:135143.

    • Search Google Scholar
    • Export Citation
  • 101.

    Rauh-HainJARodriguezNGrowdonWB. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol2012;19:959965.

    • Search Google Scholar
    • Export Citation
  • 102.

    MorrisonJHaldarKKehoeSLawrieTA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev2012;8:CD005343.

    • Search Google Scholar
    • Export Citation
  • 103.

    VergoteITropeCGAmantF. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med2010;363:943953.

  • 104.

    SteedHOzaAMMurphyJ. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int J Gynecol Cancer2006;16(Suppl 1):4753.

    • Search Google Scholar
    • Export Citation
  • 105.

    TangjitgamolSManusirivithayaSLaopaiboonMLumbiganonP. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev2009:CD006014.

    • Search Google Scholar
    • Export Citation
  • 106.

    TierstenADLiuPYSmithHO. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol2009;112:444449.

    • Search Google Scholar
    • Export Citation
  • 107.

    VandenputIVan CalsterBCapoenA. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?Br J Cancer2009;101:244249.

    • Search Google Scholar
    • Export Citation
  • 108.

    ChiDSMusaFDaoF. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol2012;124:1014.

    • Search Google Scholar
    • Export Citation
  • 109.

    FlemingGFSeidmanJLengyelE. Epithelial ovarian cancer. In: BarakatRRMarkmanMRandallME eds. Principles and Practice of Gynecologic Oncology6th ed.Philadelphia: Lippincott Williams & Wilkins; 2013:757847.

    • Search Google Scholar
    • Export Citation
  • 110.

    SchorgeJOEisenhauerEEChiDS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am2012;26:93109.

  • 111.

    WhitneyCWSpirtosN. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia: Gynecologic Oncology Group; 2009.

  • 112.

    GiedeKCKieserKDodgeJRosenB. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol2005;99:447461.

    • Search Google Scholar
    • Export Citation
  • 113.

    EarleCCSchragDNevilleBA. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst2006;98:172180.

    • Search Google Scholar
    • Export Citation
  • 114.

    du BoisAQuinnMThigpenT. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol2005;16(Suppl 8):viii7viii12.

    • Search Google Scholar
    • Export Citation
  • 115.

    SchlaerthACChiDSPoynorEA. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer2009;19:11991204.

    • Search Google Scholar
    • Export Citation
  • 116.

    SchilderJMThompsonAMDePriestPD. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol2002;87:17.

    • Search Google Scholar
    • Export Citation
  • 117.

    FaderANRosePG. Role of surgery in ovarian carcinoma. J Clin Oncol2007;25:28732883.

  • 118.

    WrightJDShahMMathewL. Fertility preservation in young women with epithelial ovarian cancer. Cancer2009;115:41184126.

  • 119.

    SatohTHataeMWatanabeY. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol2010;28:17271732.

    • Search Google Scholar
    • Export Citation
  • 120.

    GershensonDM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol2012;55:6574.

  • 121.

    BristowRETomacruzRSArmstrongDK. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol2002;20:12481259.

    • Search Google Scholar
    • Export Citation
  • 122.

    StierEABarakatRRCurtinJP. Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol1996;87:737740.

  • 123.

    EisenhauerELAbu-RustumNRSonodaY. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol2006;103:10831090.

    • Search Google Scholar
    • Export Citation
  • 124.

    du BoisAReussAPujade-LauraineE. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115:12341244.

    • Search Google Scholar
    • Export Citation
  • 125.

    ChangSJBristowRE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol2012;125:483492.

    • Search Google Scholar
    • Export Citation
  • 126.

    ElattarABryantAWinter-RoachBA. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev2011:CD007565.

    • Search Google Scholar
    • Export Citation
  • 127.

    ChiDSEisenhauerELZivanovicO. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol2009;114:2631.

    • Search Google Scholar
    • Export Citation
  • 128.

    LiuCSNagarshethNPNezhatFR. Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer?J Minim Invasive Gynecol2009;16:250262.

    • Search Google Scholar
    • Export Citation
  • 129.

    FagottiAVizzielliGDe IacoP. A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol2013;209:462.e1462.e11.

    • Search Google Scholar
    • Export Citation
  • 130.

    MagrinaJFZanagnoloVNobleBN. Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy. Gynecol Oncol2011;121:100105.

    • Search Google Scholar
    • Export Citation
  • 131.

    MoriKMNeubauerNL. Minimally invasive surgery in gynecologic oncology. ISRN Obstet Gynecol2013;2013:312982.

  • 132.

    Committee on Practice Bulletins–Gynecology. ACOG Practice Bulletin No. 126: Management of gynecologic issues in women with breast cancer. Obstet Gynecol2012;119:666682.

    • Search Google Scholar
    • Export Citation
  • 133.

    BartonDLLoprinziCGostoutB. Current management of menopausal symptoms in cancer patients. Oncology (Williston Park)2002;16:677274; discussion 75–66 79–80.

    • Search Google Scholar
    • Export Citation
  • 134.

    JenkinsMRSikonAL. Update on nonhormonal approaches to menopausal management. Cleve Clin J Med2008;75(Suppl 4):S1724.

  • 135.

    WimbergerPLehmannNKimmigR. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol2007;106:6974.

    • Search Google Scholar
    • Export Citation
  • 136.

    FischerovaDZikanMDundrPCibulaD. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist2012;17:15151533.

  • 137.

    AyhanACelikHTaskiranC. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol2003;24:223232.

    • Search Google Scholar
    • Export Citation
  • 138.

    ZanettaGBonazziCCantuM. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol2001;19:10151020.

    • Search Google Scholar
    • Export Citation
  • 139.

    LeeSJSchoverLRPartridgeAH. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol2006;24:29172931.

    • Search Google Scholar
    • Export Citation
  • 140.

    LaiCHChangTCHsuehS. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol2005;96:784791.

  • 141.

    McCluggageWGJudgeMJClarkeBA. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol2015;28:11011122.

    • Search Google Scholar
    • Export Citation
  • 142.

    OkamotoAGlasspoolRMMabuchiS. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer2014;24:S2025.

    • Search Google Scholar
    • Export Citation
  • 143.

    MagazzinoFKatsarosDOttaianoA. Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study. Int J Gynecol Cancer2011;21:10631070.

    • Search Google Scholar
    • Export Citation
  • 144.

    MassadLSGaoFHagemannIPowellM. Clinical outcomes among women with mucinous adenocarcinoma of the ovary. Gynecol Obstet Invest2015.

  • 145.

    BrulsJSimonsMOverbeekLI. A national population-based study provides insight in the origin of malignancies metastatic to the ovary. Virchows Arch2015;467:7986.

    • Search Google Scholar
    • Export Citation
  • 146.

    McCluggageWGWilkinsonN. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology2005;47:231247.

    • Search Google Scholar
    • Export Citation
  • 147.

    de WaalYRThomasCMOeiAL. Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer2009;19:11601165.

    • Search Google Scholar
    • Export Citation
  • 148.

    SatoSItamochiHKigawaJ. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci2009;100:546551.

    • Search Google Scholar
    • Export Citation
  • 149.

    MadoreJRenFFilali-MouhimA. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol2010;220:392400.

    • Search Google Scholar
    • Export Citation
  • 150.

    MackayHJBradyMFOzaAM. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer2010;20:945952.

    • Search Google Scholar
    • Export Citation
  • 151.

    BodurkaDCDeaversMTTianC. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer2012;118:30873094.

    • Search Google Scholar
    • Export Citation
  • 152.

    GershensonDMSunCCIyerRB. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol2012;125:661666.

    • Search Google Scholar
    • Export Citation
  • 153.

    GershensonDMBodurkaDCColemanRL. Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum [abstract]. J Clin Oncol2016;34:Abstract 5502.

    • Search Google Scholar
    • Export Citation
  • 154.

    PiccartMJBertelsenKJamesK. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst2000;92:699708.

    • Search Google Scholar
    • Export Citation
  • 155.

    MangiliGSigismondiCGadducciA. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer2011;21:14141421.

    • Search Google Scholar
    • Export Citation
  • 156.

    GershensonDM. Management of ovarian germ cell tumors. J Clin Oncol2007;25:29382943.

  • 157.

    BrownJFriedlanderMBackesFJ. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer2014;24:S4854.

    • Search Google Scholar
    • Export Citation
  • 158.

    GershensonDMMorrisMCangirA. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol1990;8:715720.

    • Search Google Scholar
    • Export Citation
  • 159.

    ZanagnoloVSartoriEGalleriG. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol2004;25:315320.

  • 160.

    LowJJPerrinLCCrandonAJHackerNF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer2000;89:391398.

    • Search Google Scholar
    • Export Citation
  • 161.

    MangiliGScarfoneGGadducciA. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol2010;119:4852.

    • Search Google Scholar
    • Export Citation
  • 162.

    BillmireDVinocurCRescorlaF. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg2004;39:424429; discussion 424–429.

    • Search Google Scholar
    • Export Citation
  • 163.

    MahdiHSwensenREHannaR. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer2011;105:493497.

    • Search Google Scholar
    • Export Citation
  • 164.

    VazquezIRustinGJ. Current controversies in the management of germ cell ovarian tumours. Curr Opin Oncol2013;25:539545.

  • 165.

    PectasidesDPectasidesEKassanosD. Germ cell tumors of the ovary. Cancer Treat Rev2008;34:427441.

  • 166.

    TangirJZeltermanDMaWSchwartzPE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol2003;101:251257.

    • Search Google Scholar
    • Export Citation
  • 167.

    BillmireDFCullenJWRescorlaFJ. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group. J Clin Oncol2014;32:465470.

    • Search Google Scholar
    • Export Citation
  • 168.

    CushingBGillerRAblinA. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group. Am J Obstet Gynecol1999;181:353358.

    • Search Google Scholar
    • Export Citation
  • 169.

    PattersonDMMurugaesuNHoldenL. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer2008;18:4350.

    • Search Google Scholar
    • Export Citation
  • 170.

    MarinaNMCushingBGillerR. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a Pediatric Oncology Group/Children's Cancer Group Intergroup study. J Clin Oncol1999;17:21372143.

    • Search Google Scholar
    • Export Citation
  • 171.

    BillmireDFKrailoMRodriguez-GalindoCFrazierAL. Reply to G. Mangili et al and C. Lhomme et al. J Clin Oncol2014;32:28162817.

  • 172.

    LhommeCLearyAUzanC. Adjuvant chemotherapy in stage I ovarian germ cell tumors: should indications and treatment modalities be different in young girls and adults?J Clin Oncol2014;32:28152816.

    • Search Google Scholar
    • Export Citation
  • 173.

    MangiliGSigismondiCLorussoDPignataS. Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults. J Clin Oncol2014;32:28142815.

    • Search Google Scholar
    • Export Citation
  • 174.

    BrownJShvartsmanHSDeaversMT. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol2005;97:489496.

    • Search Google Scholar
    • Export Citation
  • 175.

    WilliamsSBlessingJALiaoSY. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol1994;12:701706.

    • Search Google Scholar
    • Export Citation
  • 176.

    KangHKimTJKimWY. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol2008;111:106110.

    • Search Google Scholar
    • Export Citation
  • 177.

    SaxmanSBFinchDGoninREinhornLH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol1998;16:702706.

    • Search Google Scholar
    • Export Citation
  • 178.

    XiaoHMazumdarMBajorinDF. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol1997;15:25532558.

    • Search Google Scholar
    • Export Citation
  • 179.

    NicholsCRCatalanoPJCrawfordED. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol1998;16:12871293.

    • Search Google Scholar
    • Export Citation
  • 180.

    HintonSCatalanoPJEinhornLH. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer2003;97:18691875.

    • Search Google Scholar
    • Export Citation
  • 181.

    HorwichASleijferDTFossaSD. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol1997;15:18441852.

    • Search Google Scholar
    • Export Citation
  • 182.

    TonerGCStocklerMRBoyerMJ. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet2001;357:739745.

    • Search Google Scholar
    • Export Citation
  • 183.

    BamiasAAravantinosGKastriotisI. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group. Urol Oncol2011;29:189193.

    • Search Google Scholar
    • Export Citation
  • 184.

    DimopoulosMAPapadimitriouCHamilosG. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol2004;95:695700.

    • Search Google Scholar
    • Export Citation
  • 185.

    WilliamsSDKaudererJBurnettAF. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol2004;95:496499.

    • Search Google Scholar
    • Export Citation
  • 186.

    SalaniRBackesFJFungMF. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol2011;204:466478.

    • Search Google Scholar
    • Export Citation
  • 187.

    Reddy AmmakkanavarNMateiDAbonourREinhornLH. High-dose chemotherapy for recurrent ovarian germ cell tumors. J Clin Oncol2015;33:226227.

    • Search Google Scholar
    • Export Citation
  • 188.

    ShibataKKajiyamaHKikkawaF. Growing teratoma syndrome of the ovary showing three patterns of metastasis: a case report. Case Rep Oncol2013;6:544549.

    • Search Google Scholar
    • Export Citation
  • 189.

    MatsushitaHAraiKFukaseM. Growing teratoma syndrome of the ovary after fertility-sparing surgery and successful pregnancy. Gynecol Obstet Invest2010;69:221223.

    • Search Google Scholar
    • Export Citation
  • 190.

    AmsalemHNadjariMPrusD. Growing teratoma syndrome vs chemotherapeutic retroconversion: case report and review of the literature. Gynecol Oncol2004;92:357360.

    • Search Google Scholar
    • Export Citation
  • 191.

    DjordjevicBEuscherEDMalpicaA. Growing teratoma syndrome of the ovary: review of literature and first report of a carcinoid tumor arising in a growing teratoma of the ovary. Am J Surg Pathol2007;31:19131918.

    • Search Google Scholar
    • Export Citation
  • 192.

    BrennerDJHallEJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med2007;357:22772284.

  • 193.

    KondaguntaGVBacikJDonadioA. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol2005;23:65496555.

    • Search Google Scholar
    • Export Citation
  • 194.

    EinhornLHWilliamsSDChamnessA. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med2007;357:340348.

    • Search Google Scholar
    • Export Citation
  • 195.

    LoehrerPJSr.GoninRNicholsCR. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol1998;16:25002504.

    • Search Google Scholar
    • Export Citation
  • 196.

    HintonSCatalanoPEinhornLH. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol2002;20:18591863.

    • Search Google Scholar
    • Export Citation
  • 197.

    NicholsCRRothBJLoehrerPJ. Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol1994;21:102108.

  • 198.

    SlaytonREParkRCSilverbergSG. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer1985;56:243248.

    • Search Google Scholar
    • Export Citation
  • 199.

    MangiliGOttolinaJGadducciA. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer2013;109:2934.

    • Search Google Scholar
    • Export Citation
  • 200.

    ColomboNParmaGZanagnoloVInsingaA. Management of ovarian stromal cell tumors. J Clin Oncol2007;25:29442951.

  • 201.

    LeeIHChoiCHHongDG. Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. J Gynecol Oncol2011;22:188195.

    • Search Google Scholar
    • Export Citation
  • 202.

    Ray-CoquardIBrownJHarterP. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer2014;24:S4247.

    • Search Google Scholar
    • Export Citation
  • 203.

    ZhangMCheungMKShinJY. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary: an analysis of 376 women. Gynecol Oncol2007;104:396400.

    • Search Google Scholar
    • Export Citation
  • 204.

    WolfJBrownJ. Management of stromal tumors of the ovary: ASCO; 2008.

  • 205.

    BrownJSoodAKDeaversMT. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?Gynecol Oncol2009;113:8690.

    • Search Google Scholar
    • Export Citation
  • 206.

    SchumerSTCannistraSA. Granulosa cell tumor of the ovary. J Clin Oncol2003;21:11801189.

  • 207.

    SchneiderDTCalaminusGWessalowskiR. Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol2003;21:23572363.

  • 208.

    ParkJYJinKLKimDY. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol2012;125:8086.

    • Search Google Scholar
    • Export Citation
  • 209.

    GurumurthyMBryantAShanbhagS. Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent). Cochrane Database Syst Rev2014;4:CD006912.

    • Search Google Scholar
    • Export Citation
  • 210.

    HomesleyHDBundyBNHurteauJARothLM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol1999;72:131137.

    • Search Google Scholar
    • Export Citation
  • 211.

    PautierPGutierrez-BonnaireMReyA. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int J Gynecol Cancer2008;18:446452.

    • Search Google Scholar
    • Export Citation
  • 212.

    TeohDFreedmanRSolimanPT. Nearly 30 years of treatment for recurrent granulosa cell tumor of the ovary: a case report and review of the literature. Case Rep Oncol2010;3:1418.

    • Search Google Scholar
    • Export Citation
  • 213.

    AlhilliMMLongHJPodratzKCBakkum-GamezJN. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res2012;38:340344.

    • Search Google Scholar
    • Export Citation
  • 214.

    KorachJPerriTBeinerM. Promising effect of aromatase inhibitors on recurrent granulosa cell tumors. Int J Gynecol Cancer2009;19:830833.

    • Search Google Scholar
    • Export Citation
  • 215.

    FishmanAKudelkaAPTresukosolD. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med1996;41:393396.

    • Search Google Scholar
    • Export Citation
  • 216.

    TaoXSoodAKDeaversMT. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol2009;114:431436.

    • Search Google Scholar
    • Export Citation
  • 217.

    PacautCBourmaudARivoirardR. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol2015;38:272277.

    • Search Google Scholar
    • Export Citation
  • 218.

    GeorgeEMHerzogTJNeugutAI. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol2013;131:4245.

    • Search Google Scholar
    • Export Citation
  • 219.

    del CarmenMGBirrerMSchorgeJO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol2012;125:271277.

  • 220.

    ManoMSRosaDDAzambujaE. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer2007;17:316324.

  • 221.

    Berton-RigaudDDevouassoux-ShisheboranMLedermannJA. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer2014;24:S5560.

    • Search Google Scholar
    • Export Citation
  • 222.

    JerniganAMFaderANNutterB. Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. Obstet Gynecol Int2013;2013:490508.

    • Search Google Scholar
    • Export Citation
  • 223.

    ChunKCKimJJKimDY. Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience. Gynecol Obstet Invest2011;72:208214.

    • Search Google Scholar
    • Export Citation
  • 224.

    BrownEStewartMRyeT. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer2004;100:21482153.

  • 225.

    SilasiDAIlluzziJLKellyMG. Carcinosarcoma of the ovary. Int J Gynecol Cancer2008;18:2229.

  • 226.

    DuskaLRGarrettAEltabbakhGH. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol2002;85:459463.

    • Search Google Scholar
    • Export Citation
  • 227.

    InthasornPBealePDalrympleCCarterJ. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol2003;43:6164.

    • Search Google Scholar
    • Export Citation
  • 228.

    Rauh-HainJAGrowdonWBRodriguezN. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol2011;121:477481.

  • 229.

    LeiserALChiDSIshillNMTewWP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol2007;105:657661.

    • Search Google Scholar
    • Export Citation
  • 230.

    LoizziVCormioGCamporealeA. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. Oncology2011;80:102106.

  • 231.

    RutledgeTLGoldMAMcMeekinDS. Carcinosarcoma of the ovary: a case series. Gynecol Oncol2006;100:128132.

  • 232.

    PratJDe NictolisM. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol2002;26:11111128.

    • Search Google Scholar
    • Export Citation
  • 233.

    CadronILeunenKVan GorpT. Management of borderline ovarian neoplasms. J Clin Oncol2007;25:29282937.

  • 234.

    BarakatRRBenjaminILewisJLJr.. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol1995;59:390393.

    • Search Google Scholar
    • Export Citation
  • 235.

    LeakeJFCurrieJLRosensheinNBWoodruffJD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol1992;47:150158.

    • Search Google Scholar
    • Export Citation
  • 236.

    BarnhillDRKurmanRJBradyMF. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol1995;13:27522756.

    • Search Google Scholar
    • Export Citation
  • 237.

    PratJ. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch2012;460:237249.

    • Search Google Scholar
    • Export Citation
  • 238.

    HarterPGershensonDLhommeC. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer2014;24:S58.

    • Search Google Scholar
    • Export Citation
  • 239.

    BurgerCWPrinssenHMBaakJP. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer2000;10:181197.

  • 240.

    MoricePDenschlagDRodolakisA. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer2011;21:951963.

    • Search Google Scholar
    • Export Citation
  • 241.

    WingoSNKnowlesLMCarrickKS. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. Am J Obstet Gynecol2006;194:e2022.

    • Search Google Scholar
    • Export Citation
  • 242.

    WinterWE3rdKuceraPRRodgersW. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol2002;100:671676.

    • Search Google Scholar
    • Export Citation
  • 243.

    GershensonDMSilvaEG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer1990;65:578585.

  • 244.

    ShihKKZhouQCAghajanianC. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol2010;119:270273.

    • Search Google Scholar
    • Export Citation
  • 245.

    SuttonGPBundyBNOmuraGA. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol1991;41:230233.

    • Search Google Scholar
    • Export Citation
  • 246.

    KennedyAWHartWR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer1996;78:278286.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3041 3041 296
PDF Downloads 683 683 98
EPUB Downloads 0 0 0